Kaleido Insulin Pump System Commercialization & Development
Type 1 Diabetes
CommercialActive
Key Facts
About ViCentra
ViCentra is a commercial-stage medical device company focused on reinventing insulin pump therapy for people with diabetes. Its flagship product, the Kaleido pump, distinguishes itself through a modular, reusable design, extensive personalization options, and integration with third-party algorithms and continuous glucose monitors to form a hybrid closed-loop system. The company currently markets its solution in the Netherlands and Germany, targeting improved quality of life and glycemic control through a patient-centric, sustainable approach to durable medical equipment.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |